North American Hospital Expansion Will Advance Diagnostic Opportunities

Published
04 Dec 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
€106.11
20.1% undervalued intrinsic discount
14 Aug
€84.74
Loading
1Y
-16.1%
7D
2.7%

Author's Valuation

€106.1

20.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 7.14%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 3.19%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 5.08%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 0.76%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 0.76%

AnalystConsensusTarget has increased revenue growth from 7.5% to 8.5%.

Shared on12 Mar 25
Fair value Decreased 1.59%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.